CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CIDP drug empasiprubart enters final phase of testing
Disease control Recruiting nowThis phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for tough nerve disease: experimental drug riliprubart enters final testing
Disease control Recruiting nowThis study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New study tracks Efgartigimod's Real-World impact on CIDP patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at debilitating autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with severe autoimmune diseases like multiple sclerosis, myasthenia gravis, and neuromyelitis op…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: EARLY_PHASE1 • Sponsor: Tianjin Huanhu Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Sound waves vs. nerve disease: a new way to spot GBS and CIDP?
Knowledge-focused Recruiting nowThis study looks at whether ultrasound can detect nerve changes in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) earlier than standard tests. Researchers will compare ultrasound images with nerve conduction studies …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC